CORTNasdaqPharmaceutical Preparations

Corcept Therapeutics Inc (CORT) earnings date, market-implied expected move, and options open interest by expiry

82.84

+2.38 · +2.96%

post 79.50 −4.03%

Closed19:30 ET

Open81.21Volume1.5MMkt cap$9.0BP/E52.65EPS1.51

Day75.00 – 83.7851%52-wk28.66 – 126.3852%

CORT

Corcept Therapeutics Inc

OpenVolumeMkt capP/EEPSDiv yield

Day – 52-wk –

Expected move

No implied move.

Expected move

Inputs

Next report

Feb 23

after close · in 112 days

est.Q4 FY26

Calendar

Next report

Last report

Nov 3

after close

confirmedQ3 FY26Nov 2 close

Implied vs realized

Largest filed tie

—

Supply chain

13F top-10 QoQ

+5.69%

shares held · 10 largest managers

13F · Jun 30 '26127d lag

431 managers

Top fund weight

0.01%

CORT weight · VTI

N-PORTJun 30 '26

2 funds

Last reportshaded = implied▲▼ = realized× = |realized| ÷ implied

Corcept Therapeutics (CORT) is expected to report on Feb 23 after close (estimated date).

Implied vs realized

1 report

—≥ implied

Q2 FY26Jul 29 '26confirmed—▲+27.29%—

quarterimplied−30%0+30%realized×

Q2 FY26—▲+27.29%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Implied vs realized

Positioning

OI · 4 expiries · Nov 2 close

0.46OI · 4 expiries · Nov 2 closeP/C open interest · Nov 20 · nearest expiry

PUTS · chgexpiry · days · P/CCALLS · chgP/C

2,398+1%Nov 2017d5,214+3%

2,7900%Dec 1845d0.813,4360%0.81

9,7060%Jan 1573d0.4421,9220%0.44

766+1%Feb 19108d0.711,0860%0.71

ExpiryPutsCallsP/C

Nov 2017d2,398+1%5,214+3%0.46

Dec 1845d2,7900%3,4360%0.81

Jan 1573d9,7060%21,9220%0.44

Hatched = puts · solid = calls · bars scaled per expiry · chg = OI vs prior sessionSource: options EOD

Positioning

Linked exposure

No implied move.

Linked exposure

Revenue flow

as filedQ3 FY26

37.24%as filednet margin · revenue +32.92% QoQ · +63.97% YoY

Revenue

$340M+32.92% QoQ

Gross profit

$336M+33.23% QoQ

98.65% margin

Operating income

$115M+177.78% QoQ

33.70% margin

Pre-tax income

$120M+161.93% QoQ

Net income

$127M+194.92% QoQ

37.24% margin

Cost of revenue

$5M+13.47% QoQ

Operating expenses

$221M+4.91% QoQ

SG&A $164M

R&D $57M

Other income

$6M+20.56% QoQ

Tax benefit

$6M

Revenue$340M+32.92%

Gross profit

$336M+33.23%

98.65% margin

Operating income

$115M+177.78%

33.70% margin

Pre-tax income

$120M+161.93%

Net income

$127M+194.92%

37.24% margin

Cost of revenue

$5M+13.47%

Operating expenses

$221M+4.91%

SG&A $164M

R&D $57M

Other income$6M+20.56%

Tax benefit$6M

flow · deduction · inflow · signed % = QoQSource: SEC filings · standardized · QE Sep 30 '26 · width = $

Revenue flow

Intraday

15m bars

Hatch = extended hours · ▯ up · ▮ downSource: market data · 19:30 ET

Intraday

Event sensitivity

GDP ×1.71· ±4.4% vs ±2.6% · 19 releases

eventrelease day|move|up · n×base

GDPgross domestic product±4.4%9 of 19×1.71

PCEpersonal income & outlays±3.9%10 of 19×1.51

PPIproducer prices±3.6%4 of 10×1.39

CPROFcorporate profits±2.6%6 of 12×1.01

NFPjobs report±2.4%5 of 10×0.92

FOMCrate decision±2.3%14 of 24×0.91

CPIconsumer prices±1.8%5 of 10×0.69

Bar = avg |move| to ±5% · tick = ±2.6% avg day · ×base = |move| ÷ ±2.6% · min 6 releases

Earnings history

EPS 1.01 · consensus —

Quarter	Reported	EPS	Consensus
Q3 FY26	—	1.01	—
Q2 FY26	Jul 29 '26 · confirmed	0.36	—
Q1 FY26	—	-0.30	—

Source: filed financials

Methodology

ties · implied moves · holdersMethod